| Symbol | PABAF |
|---|---|
| Name | PATRYS LTD. |
| Sector | UNDEFINED |
| Region | Oceania |
| Industry | - |
| Address | 3000 Australia VA Suite 2, Level 11 385 Bourke Street |
| Telephone | +61 03 9670 3273 |
| Fax | — |
| — | |
| Website | https://www.patrys.com/ |
| Incorporation | AU |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 6/30 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: ASX - Australian Securities Exchange |
| CIK | — |
| Description | Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. Additional info from OTC: |
No news found.